Brain Cancer @ Leeds

Dr Erica Wilson – Senior Research Fellow

ericaContact Information

Dr Erica Wilson
Translational Neuro-oncology
Leeds Institute of Cancer and Pathology
Wellcome Trust Brenner Building
St James’s University Hospital
Beckett street, Leeds
United Kingdom
tel: +44 (0) 113 343 8638


My current work focuses on immunology and immunotherapeutic strategies in Glioblastoma. I aim to understand how the immune system responds to immunotherapy in the brain, and develop a better understanding of this complex and immune tolerant environment. Many of my research questions centre around which of the resident and infiltrating immune cells respond to oncolytic viruses and how we might manipulate them for improved therapeutic effect within the unique microenvironment of the brain.




Holmes TD, Wilson EB, Black EVI, Benest AV, , Vaz C, Tan B, Tanavde VM, Cook GP.
Licensed human natural killer cells aid dendritic maturation via TNSF14/LIGHT.
Proc Natl Acad Sci U S A. 2014, 111(52):E5688-96. doi: 10.1073/pnas.1411072112. Epub 2014 Dec 15.

El-Sherbiny YM1, Holmes TD, Wetherill LF, Black EV, Wilson EB, Phillips SL, Scott GB, Adair RA, Dave R, Scott KJ, Morgan RS, Coffey M, Toogood GJ, Melcher AA, Cook GP.
Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo.
Clin Exp Immunol. 2015, 180(1):98-107. doi: 10.1111/cei.12562.

Wilson EB, El-Jawhari J, Neilson A, Jennings V, Hall G, Melcher A, Meade JL, Cook GP.
Reversible TGF-β mediated inhibition of natural killer cells in the human tumour microenvironment.
PLoS One. 2011, 6(9):e22842. Epub 2011 Sep 6

Scott GB, Bowles PA, Wilson EB, Meade JL, Low BC, Davison A, Blair GE, Cook GP
Identification of the BCL2/adenovirus E1B-19K protein-interacting protein 2 (BNIP-2) as a granzyme B target during human natural killer cell-mediated killing.
Biochem J. 2010, Oct 11;431(3):423-31.

Meade JL, Wilson EB, Holmes TD, de Wynter EA, Brett P, Straszynski L, Ballard PA, Trapani JA, McDermott MF, Cook GP.
Proteolytic activation of the cytotoxic phenotype during human NK cell development.
J Immunol. 2009, Jul 15;183(2):803-13.

Wilson EB, Paranchoniak CA, Carpenito C, Mager DL, Takei F.
Expression of murine killer immunoglobulin-like receptor KIRL1 on CD1d-independent NK1.1(+) T cells.
Immunogenetics. 2007, 59 641-651.

Watkins NA, O’Connor M,N , Rankin A, Jennings N, Wilson EB, Harmer IJ, Davies L, Smethurst PA, Dudbridge F, Farndale RW and Ouwehand WH.
Definition of novel GP6 polymorphisms and major difference in haplotype frequencies between populations by a combination of in-depth exon resequencing and genotyping with tag single nucleotide polymorphisms.
J Thromb Haemost. 2006, Jun;4(6):1197-205.

Smethurst PA, Joutsi-Korhonen L, O’Connor MN, Wilson EB, Jennings NS, Garner SF, Zhang Y, Knight CG, Dafforn TR, Buckle A, Ijsseldijk MJW, Groot PG de, Watkins NA, Farndale RW and Ouwehand WH.
Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody.
Blood: 2004, 103, 903-911.

Kotecha MT, Afghan RK, Vasilikopoulou E, Wilson EB, Marsh P, Kast M, Davies DH and Caparros-Wanderley W.
Enhanced tumour growth after DNA vaccination against human papilloma virus E7 oncoprotein: evidence for tumour-induced immune deviation.
Vaccine: 2003, 21, 2506-15.

© Copyright Leeds 2020